Launching Adakveo(R): First treatment for sickle cell in 20 years
Havas Life Medicom
Imagine living with the unpredictability of an illness where episodes of severe pain can strike at any moment. Then imagine there’s been no new treatments in over 20 years. For many of the 15,000 people living with sickle cell disorder (SCD) in the UK, this has been their reality.
Introducing, Adakveo®, would be a significant step forward in advancing health equity for those living with SCD. At a time when COVID was capturing headlines, successful launch comms needed to break through by leveraging the collaboration between the NHS, NICE and advocacy to draw attention to a new era of treatment.